BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sato Pharmaceutical Co.\, Ltd. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Sato Pharmaceutical Co.\, Ltd.'s 
 drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07916480-1479@assetmemo.bio
DTSTAMP:20261121T005738Z
DTSTART;VALUE=DATE:20280427
DTEND;VALUE=DATE:20280428
SUMMARY:Roflumilast (Zoryve): Phase 3 readout est. (NCT07916480)
DESCRIPTION:Roflumilast (Zoryve)\, phase 3\, Atopic Dermatitis.\nStudy: Rof
 lumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis\nEstimated pr
 imary completion: 27 April 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/roflumilast-zoryve#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07916480
URL:https://assetmemo.bio/drug/roflumilast-zoryve#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
